BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Herring WJ, Connor KM, Ivgy-May N, Snyder E, Liu K, Snavely DB, Krystal AD, Walsh JK, Benca RM, Rosenberg R, Sangal RB, Budd K, Hutzelmann J, Leibensperger H, Froman S, Lines C, Roth T, Michelson D. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. Biol Psychiatry 2016;79:136-48. [PMID: 25526970 DOI: 10.1016/j.biopsych.2014.10.003] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Blackman J, Swirski M, Clynes J, Harding S, Leng Y, Coulthard E. Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review. J Sleep Res 2021;30:e13229. [PMID: 33289311 DOI: 10.1111/jsr.13229] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
2 Neylan TC, Richards A, Metzler TJ, Ruoff LM, Varbel J, O'Donovan A, Sivasubramanian M, Motraghi T, Hlavin J, Batki SL, Inslicht SS, Samuelson K, Morairty SR, Kilduff TS. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep 2020;43:zsaa080. [PMID: 32303763 DOI: 10.1093/sleep/zsaa080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
3 Dujardin S, Pijpers A, Pevernagie D. Prescription Drugs Used in Insomnia. Sleep Med Clin 2020;15:133-45. [PMID: 32386689 DOI: 10.1016/j.jsmc.2020.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. J Clin Sleep Med 2016;12:1215-25. [PMID: 27397664 DOI: 10.5664/jcsm.6116] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
5 Jacobson LH, Chen S, Mir S, Hoyer D. Orexin OX2 Receptor Antagonists as Sleep Aids. In: Lawrence AJ, de Lecea L, editors. Behavioral Neuroscience of Orexin/Hypocretin. Cham: Springer International Publishing; 2017. pp. 105-36. [DOI: 10.1007/7854_2016_47] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
6 Walsh JH, Maddison KJ, Rankin T, Murray K, McArdle N, Ree MJ, Hillman DR, Eastwood PR. Treating Insomnia Symptoms with Medicinal Cannabis: A Randomized, Cross-Over Trial of the Efficacy of a Cannabinoid Medicine Compared with Placebo. Sleep 2021:zsab149. [PMID: 34115851 DOI: 10.1093/sleep/zsab149] [Reference Citation Analysis]
7 Christopher JA, Aves SJ, Brown J, Errey JC, Klair SS, Langmead CJ, Mace OJ, Mould R, Patel JC, Tehan BG, Zhukov A, Marshall FH, Congreve M. Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. Med Chem Commun 2015;6:947-55. [DOI: 10.1039/c5md00027k] [Cited by in Crossref: 11] [Article Influence: 1.6] [Reference Citation Analysis]
8 Izuhara M, Miura S, Otsuki K, Nagahama M, Hayashida M, Hashioka S, Asou H, Kitagaki H, Inagaki M. Magnetic Resonance Spectroscopy in the Ventral Tegmental Area Distinguishes Responders to Suvorexant Prior to Treatment: A 4-Week Prospective Cohort Study. Front Psychiatry 2021;12:714376. [PMID: 34497544 DOI: 10.3389/fpsyt.2021.714376] [Reference Citation Analysis]
9 Kishi T, Matsunaga S, Iwata N. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. PLoS One 2015;10:e0136910. [PMID: 26317363 DOI: 10.1371/journal.pone.0136910] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
10 Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J. Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders. Expert Opinion on Drug Metabolism & Toxicology 2020;16:1063-78. [DOI: 10.1080/17425255.2020.1817380] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
11 Choi Y, Raymer BK. Sleep modulating agents. Bioorg Med Chem Lett 2019;29:2025-33. [PMID: 31307886 DOI: 10.1016/j.bmcl.2019.06.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Jin M, Feng D, Liu G, Wan S. Two-level approaches to missing data in longitudinal trials with daily patient-reported outcomes. Stat Methods Med Res 2020;29:1935-49. [DOI: 10.1177/0962280219880432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
13 Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data. Psychopharmacology (Berl) 2017;234:1703-11. [PMID: 28265715 DOI: 10.1007/s00213-017-4573-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
14 Feng D, Svetnik V. Using the Latent Correlations to Measure the Association Between Continuous and Binary Markers With Repeated Measurements. Statistics in Biopharmaceutical Research 2018;10:244-54. [DOI: 10.1080/19466315.2017.1379432] [Reference Citation Analysis]
15 Roehrs T, Verster JC, Koshorek G, Withrow D, Roth T. How representative are insomnia clinical trials? Sleep Med 2018;51:118-23. [PMID: 30144651 DOI: 10.1016/j.sleep.2018.06.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
16 Dujardin S, Pijpers A, Pevernagie D. Prescription Drugs Used in Insomnia. Sleep Medicine Clinics 2018;13:169-82. [DOI: 10.1016/j.jsmc.2018.03.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
17 Landry I, Nakai K, Ferry J, Aluri J, Hall N, Lalovic B, Moline ML. Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults. Clin Pharmacol Drug Dev 2021;10:153-65. [PMID: 32468649 DOI: 10.1002/cpdd.817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
18 Connor KM, Ceesay P, Hutzelmann J, Snavely D, Krystal AD, Trivedi MH, Thase M, Lines C, Herring WJ, Michelson D. Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. Int J Neuropsychopharmacol 2017;20:613-8. [PMID: 28582570 DOI: 10.1093/ijnp/pyx033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
19 Colagiuri B, Sharpe L, Ambarchi Z, Glozier N, Bartlett D, Costa DSJ, Scott A. Open-label placebo for insomnia (OPIN): study protocol for a cohort multiple randomised controlled trial. BMJ Open 2021;11:e044045. [PMID: 33637548 DOI: 10.1136/bmjopen-2020-044045] [Reference Citation Analysis]
20 Herring WJ, Connor KM, Snyder E, Snavely DB, Morin CM, Lines C, Michelson D. Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data. Sleep Medicine 2019;56:219-23. [DOI: 10.1016/j.sleep.2018.09.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Ishibashi Y, Nishitani R, Shimura A, Takeuchi A, Touko M, Kato T, Chiba S, Ashidate K, Ishiwata N, Ichijo T, Sasabe M. Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study. PLoS One 2020;15:e0238723. [PMID: 32916693 DOI: 10.1371/journal.pone.0238723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Wilson S, Anderson K, Baldwin D, Dijk DJ, Espie A, Espie C, Gringras P, Krystal A, Nutt D, Selsick H, Sharpley A. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. J Psychopharmacol 2019;33:923-47. [PMID: 31271339 DOI: 10.1177/0269881119855343] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 20.7] [Reference Citation Analysis]
23 Svetnik V, Snyder ES, Tao P, Scammell TE, Roth T, Lines C, Herring WJ. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts. Sleep 2018;41. [DOI: 10.1093/sleep/zsx178] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
24 Krystal AD, Prather AA, Ashbrook LH. The assessment and management of insomnia: an update. World Psychiatry 2019;18:337-52. [PMID: 31496087 DOI: 10.1002/wps.20674] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
25 Campbell EJ, Marchant NJ, Lawrence AJ. A sleeping giant: Suvorexant for the treatment of alcohol use disorder? Brain Res 2020;1731:145902. [PMID: 30081035 DOI: 10.1016/j.brainres.2018.08.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
26 Kärppä M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, Perdomo C, Inoue Y, Ishikawa K, Kubota N. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep 2020;43:zsaa123. [PMID: 32585700 DOI: 10.1093/sleep/zsaa123] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
27 Okino K, Yamada H, Tomioka H, Nozaki S, Iwanami A, Inamoto A. Use of Suvorexant and Antipsychotics in the Treatment of Delirium After Infectious Diseases: A Retrospective Study. J Clin Psychopharmacol 2021;41:589-93. [PMID: 34411006 DOI: 10.1097/JCP.0000000000001450] [Reference Citation Analysis]
28 Jiang B, He D, Guo Z, Gao Z. Dynamic features of placebo effects addressing persistent insomnia disorder: A meta‐analysis of placebo‐controlled randomized clinical trials. J Sleep Res 2020;29. [DOI: 10.1111/jsr.12997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant. Nat Sci Sleep. 2016;8:239-247. [PMID: 27471419 DOI: 10.2147/nss.s76910] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
30 Nishimura S, Nakao M. Cost-effectiveness analysis of suvorexant for the treatment of Japanese elderly patients with chronic insomnia in a virtual cohort. Journal of Medical Economics 2018;21:698-703. [DOI: 10.1080/13696998.2018.1466710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. The American Journal of Geriatric Psychiatry 2017;25:791-802. [DOI: 10.1016/j.jagp.2017.03.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
32 Sieminski M, Szypenbejl J, Partinen E. Orexins, Sleep, and Blood Pressure. Curr Hypertens Rep. 2018;20:79. [PMID: 29992504 DOI: 10.1007/s11906-018-0879-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
33 Fine L. Pharmacologic Approach to Insomnia. Phys Med Rehabil Clin N Am 2020;31:255-64. [PMID: 32279728 DOI: 10.1016/j.pmr.2020.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, Snyder E, Snavely D, Michelson D, Roth T, Herring WJ. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia. Int J Neuropsychopharmacol 2016;19:pyw022. [PMID: 26979830 DOI: 10.1093/ijnp/pyw022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
35 Zeitzer JM. The neurobiological underpinning of the circadian wake signal. Biochem Pharmacol 2021;191:114386. [PMID: 33359009 DOI: 10.1016/j.bcp.2020.114386] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Kawabe K, Horiuchi F, Ochi M, Nishimoto K, Ueno SI, Oka Y. Suvorexant for the Treatment of Insomnia in Adolescents. J Child Adolesc Psychopharmacol 2017;27:792-5. [PMID: 28520464 DOI: 10.1089/cap.2016.0206] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
37 Kale HP, Qureshi ZP, Shah R, Khandker R, Botteman M, Meng W, Benca R. Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant. Adv Ther 2021;38:5221-37. [PMID: 34463922 DOI: 10.1007/s12325-021-01891-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Gao XB, Hermes G. Neural plasticity in hypocretin neurons: the basis of hypocretinergic regulation of physiological and behavioral functions in animals. Front Syst Neurosci 2015;9:142. [PMID: 26539086 DOI: 10.3389/fnsys.2015.00142] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
39 Dmitrienko A, D'agostino RB. Editorial: Multiplicity issues in clinical trials: Editorial: Multiplicity Issues in Clinical Trials. Statist Med 2017;36:4423-6. [DOI: 10.1002/sim.7506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
40 Krystal AD, Prather AA. Sleep Pharmacogenetics: The Promise of Precision Medicine. Sleep Med Clin 2019;14:317-31. [PMID: 31375201 DOI: 10.1016/j.jsmc.2019.05.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
41 Pillai V, Roth T, Roehrs T, Moss K, Peterson EL, Drake CL. Effectiveness of Benzodiazepine Receptor Agonists in the Treatment of Insomnia: An Examination of Response and Remission Rates. Sleep 2017;40. [PMID: 28364510 DOI: 10.1093/sleep/zsw044] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
42 Morin CM, Drake CL, Harvey AG, Krystal AD, Manber R, Riemann D, Spiegelhalder K. Insomnia disorder. Nat Rev Dis Primers 2015;1:15026. [PMID: 27189779 DOI: 10.1038/nrdp.2015.26] [Cited by in Crossref: 177] [Cited by in F6Publishing: 140] [Article Influence: 25.3] [Reference Citation Analysis]
43 Hatano M, Kamei H, Inagaki R, Matsuzaki H, Hanya M, Yamada S, Iwata N. Assessment of Switching to Suvorexant versus the Use of Add-on Suvorexant in Combination with Benzodiazepine Receptor Agonists in Insomnia Patients: A Retrospective Study. Clin Psychopharmacol Neurosci 2018;16:184-9. [PMID: 29739132 DOI: 10.9758/cpn.2018.16.2.184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi L, Satlin A. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Sleep Med 2017;13:1289-99. [PMID: 29065953 DOI: 10.5664/jcsm.6800] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
45 Tampi RR, Manikkara G, Balachandran S, Taparia P, Hrisko S, Srinivasan S, Tampi DJ. Suvorexant for insomnia in older adults: a perspective review. Drugs Context 2018;7:212517. [PMID: 29445409 DOI: 10.7573/dic.212517] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
46 Kobayashi I, Mellman TA, Cannon A, Brown I, Boadi L, Howell MK, Lavela P, Sandhu I. Blocking the orexin system following therapeutic exposure promoted between session habituation, but not PTSD symptom reduction. J Psychiatr Res 2021;145:222-9. [PMID: 34933185 DOI: 10.1016/j.jpsychires.2021.12.027] [Reference Citation Analysis]
47 Al-Kuraishy HM, Abdulhadi MH, Hussien NR, Al-Niemi MS, Rasheed HA, Al-Gareeb AI. Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review. Brain Circ 2020;6:70-80. [PMID: 33033776 DOI: 10.4103/bc.bc_42_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
48 Uemura N, McCrea J, Sun H, Donikyan M, Zammit G, Liu R, Louridas B, Marsilio S, Lines C, Troyer MD, Wagner J. Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects. J Clin Pharmacol 2015;55:1093-100. [PMID: 25903940 DOI: 10.1002/jcph.523] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
49 Svetnik V, Snyder ES, Tao P, Roth T, Lines C, Herring WJ. How well can a large number of polysomnography sleep measures predict subjective sleep quality in insomnia patients? Sleep Medicine 2020;67:137-46. [DOI: 10.1016/j.sleep.2019.08.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Sun H, Snyder E, Koch GG. Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints. J Biopharm Stat 2018;28:189-211. [PMID: 28992425 DOI: 10.1080/10543406.2017.1378664] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
51 Hirano A, Hsu PK, Zhang L, Xing L, McMahon T, Yamazaki M, Ptáček LJ, Fu YH. DEC2 modulates orexin expression and regulates sleep. Proc Natl Acad Sci U S A 2018;115:3434-9. [PMID: 29531056 DOI: 10.1073/pnas.1801693115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
52 Shigetsura Y, Imai S, Endo H, Shimizu Y, Ueda K, Murai T, Itohara K, Nakagawa S, Yonezawa A, Ikemi Y, Fukatsu S, Kitada N, Terada T, Nakagawa T, Matsubara K. Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder. Clin Neuropharm 2022;Publish Ahead of Print. [DOI: 10.1097/wnf.0000000000000499] [Reference Citation Analysis]
53 Keks NA, Hope J, Keogh S. Suvorexant: scientifically interesting, utility uncertain. Australas Psychiatry 2017;25:622-4. [PMID: 28994603 DOI: 10.1177/1039856217734677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
54 Soya S, Sakurai T. Orexin as a modulator of fear-related behavior: Hypothalamic control of noradrenaline circuit. Brain Res 2020;1731:146037. [PMID: 30481504 DOI: 10.1016/j.brainres.2018.11.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
55 Sullinger S, Bryand K, Kerrigan S. Identification of Suvorexant in Urine Using Liquid Chromatography-Quadrupole/Time-of-Flight Mass Spectrometry (LC-Q/TOF-MS). J Anal Toxicol 2017;41:224-9. [PMID: 28035034 DOI: 10.1093/jat/bkw132] [Reference Citation Analysis]
56 Chow M, Cao M. The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress. Nat Sci Sleep 2016;8:81-6. [PMID: 27051324 DOI: 10.2147/NSS.S76711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
57 Lane JM, Liang J, Vlasac I, Anderson SG, Bechtold DA, Bowden J, Emsley R, Gill S, Little MA, Luik AI, Loudon A, Scheer FA, Purcell SM, Kyle SD, Lawlor DA, Zhu X, Redline S, Ray DW, Rutter MK, Saxena R. Genome-wide association analyses of sleep disturbance traits identify new loci and highlight shared genetics with neuropsychiatric and metabolic traits. Nat Genet 2017;49:274-81. [PMID: 27992416 DOI: 10.1038/ng.3749] [Cited by in Crossref: 173] [Cited by in F6Publishing: 147] [Article Influence: 28.8] [Reference Citation Analysis]
58 Uchiyama M, Kambe D, Imadera Y, Kajiyama Y, Ogo H, Uchimura N. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study. Psychopharmacology (Berl) 2022. [PMID: 35296912 DOI: 10.1007/s00213-022-06089-6] [Reference Citation Analysis]
59 Matsumura T, Terada J, Yoshimura C, Koshikawa K, Kinoshita T, Yahaba M, Nagashima K, Sakao S, Tatsumi K. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience. Drug Des Devel Ther 2019;13:809-16. [PMID: 30880914 DOI: 10.2147/DDDT.S197237] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
60 Yee KL, Mccrea J, Panebianco D, Liu W, Lewis N, Cabalu T, Ramael S, Wrishko RE. Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men. Clin Drug Investig 2018;38:631-8. [DOI: 10.1007/s40261-018-0650-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
61 Roth T, Rosenberg R, Morin CM, Yardley J, Pinner K, Perdomo C, Atkins N, Pappadopulos E, Malhotra M, Moline M. Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder. Sleep Medicine 2022. [DOI: 10.1016/j.sleep.2022.01.024] [Reference Citation Analysis]
62 Ikeda S, Azuma M, Fujimoto K, Shibahara H, Inoue S, Moline M, Ishii M, Mishima K. Cost-effectiveness analysis of lemborexant for treating insomnia in Japan: a model-based projection, incorporating the risk of falls, motor vehicle collisions, and workplace accidents. Psychol Med 2022;:1-13. [PMID: 35506334 DOI: 10.1017/S0033291722000356] [Reference Citation Analysis]
63 Uslaner JM, Herring WJ, Coleman PJ. The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. ACS Pharmacol Transl Sci 2020;3:161-8. [PMID: 32259095 DOI: 10.1021/acsptsci.9b00110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Dauvilliers Y, Zammit G, Fietze I, Mayleben D, Seboek Kinter D, Pain S, Hedner J. Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder. Ann Neurol 2020;87:347-56. [DOI: 10.1002/ana.25680] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
65 Atkin T, Comai S, Gobbi G. Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacol Rev 2018;70:197-245. [PMID: 29487083 DOI: 10.1124/pr.117.014381] [Cited by in Crossref: 89] [Cited by in F6Publishing: 57] [Article Influence: 22.3] [Reference Citation Analysis]
66 Kripke DF. Is suvorexant a better choice than alternative hypnotics? F1000Res 2015;4:456. [PMID: 26594338 DOI: 10.12688/f1000research.6845.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
67 Struyk A, Gargano C, Drexel M, Stoch SA, Svetnik V, Ma J, Mayleben D. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects. Eur Neuropsychopharmacol 2016;26:1649-56. [PMID: 27554636 DOI: 10.1016/j.euroneuro.2016.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
68 Kuriyama A, Tabata H. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Med Rev 2017;35:1-7. [PMID: 28365447 DOI: 10.1016/j.smrv.2016.09.004] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
69 Kishi T, Nomura I, Matsuda Y, Sakuma K, Okuya M, Ikuta T, Iwata N. Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis. J Psychiatr Res 2020;128:68-74. [PMID: 32531478 DOI: 10.1016/j.jpsychires.2020.05.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
70 Spiegelhalder K, Nissen C, Riemann D. Clinical Sleep-Wake Disorders II: Focus on Insomnia and Circadian Rhythm Sleep Disorders. Handb Exp Pharmacol 2019;253:261-76. [PMID: 28707143 DOI: 10.1007/164_2017_40] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
71 Asai Y, Sano H, Miyazaki M, Iwakura M, Maeda Y, Hara M. Suvorexant (Belsomra® Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey. Drugs R D 2019;19:27-46. [PMID: 30552562 DOI: 10.1007/s40268-018-0256-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
72 Snyder E, Ma J, Svetnik V, Connor KM, Lines C, Michelson D, Herring WJ. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Sleep Med 2016;19:93-100. [PMID: 27198953 DOI: 10.1016/j.sleep.2015.10.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
73 Li SB, de Lecea L. The hypocretin (orexin) system: from a neural circuitry perspective. Neuropharmacology 2020;167:107993. [PMID: 32135427 DOI: 10.1016/j.neuropharm.2020.107993] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
74 Mantua J, Bessey AF, Mickelson CA, Choynowski JJ, Noble JJ, Burke TM, McKeon AB, Sowden WJ. Sleep and high-risk behavior in military service members: a mega-analysis of four diverse U.S. Army units. Sleep 2021;44:zsaa221. [PMID: 33125489 DOI: 10.1093/sleep/zsaa221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
75 He D, Jiang B, Guo Z, Mu Q, Mcclure MA. Biphasic feature of placebo response in primary insomnia: pooled analysis of data from randomized controlled clinical trials of orexin receptor antagonists. Sleep 2020;43:zsz238. [PMID: 31593985 DOI: 10.1093/sleep/zsz238] [Reference Citation Analysis]
76 Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, Pain S, Kinter DS, Roth T. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. The Lancet Neurology 2022;21:125-39. [DOI: 10.1016/s1474-4422(21)00436-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement 2020;16:541-51. [PMID: 31944580 DOI: 10.1002/alz.12035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
78 Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, Palcza J, Li X, Laethem T, Heirman I, Bautmans A, Troyer MD, Wrishko R, McCrea J. On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers. Sleep 2015;38:1803-13. [PMID: 26039969 DOI: 10.5665/sleep.5168] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
79 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
80 Amodeo LR, Wills DN, Sanchez-Alavez M, Ehlers CL. Effects of an Orexin-2 Receptor Antagonist on Sleep and Event-Related Oscillations in Female Rats Exposed to Chronic Intermittent Ethanol During Adolescence. Alcohol Clin Exp Res 2020;44:1378-88. [PMID: 32424852 DOI: 10.1111/acer.14361] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
81 Yao L, Ramirez AD, Roecker AJ, Fox SV, Uslaner JM, Smith SM, Hodgson R, Coleman PJ, Renger JJ, Winrow CJ, Gotter AL. The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine. J Neurochem 2017;142:204-14. [PMID: 28444767 DOI: 10.1111/jnc.14055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
82 Jin M, Liu G. Estimands and estimators of two-level methods using return to baseline strategy for longitudinal clinical trials with incomplete daily patient reported outcomes. J Biopharm Stat 2021;:1-14. [PMID: 34162312 DOI: 10.1080/10543406.2021.1934855] [Reference Citation Analysis]
83 Gao F, Liu T, Tuo M, Chi S. The role of orexin in Alzheimer disease: From sleep-wake disturbance to therapeutic target. Neurosci Lett 2021;765:136247. [PMID: 34530113 DOI: 10.1016/j.neulet.2021.136247] [Reference Citation Analysis]
84 Bland H, Li X, Mangin E, Yee KL, Lines C, Herring WJ, Gillespie G. Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning. J Clin Psychopharmacol 2021;41:414-20. [PMID: 34181362 DOI: 10.1097/JCP.0000000000001439] [Reference Citation Analysis]
85 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
86 Abad VC, Guilleminault C. Insomnia in Elderly Patients: Recommendations for Pharmacological Management. Drugs Aging 2018;35:791-817. [PMID: 30058034 DOI: 10.1007/s40266-018-0569-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 8.5] [Reference Citation Analysis]
87 Chong JX, Buckingham KJ, Jhangiani SN, Boehm C, Sobreira N, Smith JD, Harrell TM, McMillin MJ, Wiszniewski W, Gambin T, Coban Akdemir ZH, Doheny K, Scott AF, Avramopoulos D, Chakravarti A, Hoover-Fong J, Mathews D, Witmer PD, Ling H, Hetrick K, Watkins L, Patterson KE, Reinier F, Blue E, Muzny D, Kircher M, Bilguvar K, López-Giráldez F, Sutton VR, Tabor HK, Leal SM, Gunel M, Mane S, Gibbs RA, Boerwinkle E, Hamosh A, Shendure J, Lupski JR, Lifton RP, Valle D, Nickerson DA, Bamshad MJ; Centers for Mendelian Genomics. The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities. Am J Hum Genet 2015;97:199-215. [PMID: 26166479 DOI: 10.1016/j.ajhg.2015.06.009] [Cited by in Crossref: 418] [Cited by in F6Publishing: 346] [Article Influence: 59.7] [Reference Citation Analysis]
88 Snyder ES, Tao P, Svetnik V, Lines C, Herring WJ. Use of the single-item Patient Global Impression-Severity scale as a self-reported assessment of insomnia severity. J Sleep Res 2021;30:e13141. [PMID: 33210445 DOI: 10.1111/jsr.13141] [Reference Citation Analysis]
89 Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. J Clin Sleep Med 2016;12:9-17. [PMID: 26194728 DOI: 10.5664/jcsm.5382] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
90 Roth T, Mayleben D, Feldman N, Lankford A, Grant T, Nofzinger E. A novel forehead temperature-regulating device for insomnia: a randomized clinical trial. Sleep 2018;41. [PMID: 29648642 DOI: 10.1093/sleep/zsy045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
91 Palman AD. [Sleep and its' disturbanses in chronic obstructive pulmonary disease]. Zh Nevrol Psikhiatr Im S S Korsakova 2018;118:113-8. [PMID: 30059060 DOI: 10.17116/jnevro201811842113] [Reference Citation Analysis]
92 Fang H, Tu S, Sheng J, Shao A. Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med 2019;23:2324-32. [PMID: 30734486 DOI: 10.1111/jcmm.14170] [Cited by in Crossref: 95] [Cited by in F6Publishing: 81] [Article Influence: 31.7] [Reference Citation Analysis]
93 Yardley J, Kärppä M, Inoue Y, Pinner K, Perdomo C, Ishikawa K, Filippov G, Kubota N, Moline M. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Med 2021;80:333-42. [PMID: 33636648 DOI: 10.1016/j.sleep.2021.01.048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
94 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
95 Fragale JE, James MH, Avila JA, Spaeth AM, Aurora RN, Langleben D, Aston-Jones G. The Insomnia-Addiction Positive Feedback Loop: Role of the Orexin System. Front Neurol Neurosci 2021;45:117-27. [PMID: 34052815 DOI: 10.1159/000514965] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Seigneur E, de Lecea L. Hypocretin (Orexin) Replacement Therapies. Medicine in Drug Discovery 2020;8:100070. [DOI: 10.1016/j.medidd.2020.100070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL, Garson SL, Lepeleire ID, Calder N, Rosen L, Struyk A, Coleman PJ, Herring WJ, Renger JJ, Winrow CJ. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Sci Rep 2016;6:27147. [PMID: 27256922 DOI: 10.1038/srep27147] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
98 Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatr Dis Treat 2021;17:2549-66. [PMID: 34393484 DOI: 10.2147/NDT.S297504] [Reference Citation Analysis]
99 Sano H, Asai Y, Miyazaki M, Iwakura M, Maeda Y, Hara M. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey. Expert Opin Drug Saf 2019;18:1109-18. [PMID: 31478753 DOI: 10.1080/14740338.2019.1657091] [Reference Citation Analysis]
100 Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, Mergenhagen KA. Review of Safety and Efficacy of Sleep Medicines in Older Adults. Clinical Therapeutics 2016;38:2340-72. [DOI: 10.1016/j.clinthera.2016.09.010] [Cited by in Crossref: 144] [Cited by in F6Publishing: 109] [Article Influence: 24.0] [Reference Citation Analysis]
101 Vermeeren A, Vets E, Vuurman EF, Van Oers AC, Jongen S, Laethem T, Heirman I, Bautmans A, Palcza J, Li X, Troyer MD, Wrishko R, McCrea J, Sun H. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly. Psychopharmacology (Berl) 2016;233:3341-51. [PMID: 27424295 DOI: 10.1007/s00213-016-4375-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
102 Jiang B, He D, Gao Z. Efficacy and Placebo Response of Multimodal Treatments for Primary Insomnia: A Network Meta-Analysis. Clin Neuropharm 2019;42:197-202. [DOI: 10.1097/wnf.0000000000000369] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 De Boer P, Drevets WC, Rofael H, van der Ark P, Kent JM, Kezic I, Parapatics S, Dorffner G, van Gerven J, Beneš H, Keicher C, Jahn H, Seiden DJ, Luthringer R. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. J Psychopharmacol 2018;32:668-77. [PMID: 29848147 DOI: 10.1177/0269881118773745] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
104 Sangal RB. Efficacy and safety of esmirtazapine in adult insomnia: unsupported statements about residual daytime effects. J Clin Sleep Med 2021;17:341. [PMID: 33100265 DOI: 10.5664/jcsm.8912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Flaxer JM, Heyer A, Francois D. Evidenced-Based Review and Evaluation of Clinical Significance: Nonpharmacological and Pharmacological Treatment of Insomnia in the Elderly. Am J Geriatr Psychiatry 2021;29:585-603. [PMID: 33218915 DOI: 10.1016/j.jagp.2020.10.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Stahl SM. Mechanism of action of suvorexant. CNS Spectr 2016;21:215-8. [DOI: 10.1017/s1092852916000225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
107 Petrous J, Furmaga K. Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts. BMJ Case Rep 2017;2017:bcr-2017-222037. [PMID: 29066641 DOI: 10.1136/bcr-2017-222037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
108 Porwal A, Yadav YC, Pathak K, Yadav R. An Update on Assessment, Therapeutic Management, and Patents on Insomnia. Biomed Res Int 2021;2021:6068952. [PMID: 34708126 DOI: 10.1155/2021/6068952] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Flanigan ME, Aleyasin H, Li L, Burnett CJ, Chan KL, LeClair KB, Lucas EK, Matikainen-Ankney B, Durand-de Cuttoli R, Takahashi A, Menard C, Pfau ML, Golden SA, Bouchard S, Calipari ES, Nestler EJ, DiLeone RJ, Yamanaka A, Huntley GW, Clem RL, Russo SJ. Orexin signaling in GABAergic lateral habenula neurons modulates aggressive behavior in male mice. Nat Neurosci 2020;23:638-50. [PMID: 32284606 DOI: 10.1038/s41593-020-0617-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
110 Kaushik MK, Aritake K, Cherasse Y, Imanishi A, Kanbayashi T, Urade Y, Yanagisawa M. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice. Sleep 2021:zsab043. [PMID: 33609365 DOI: 10.1093/sleep/zsab043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Takeuchi Y, Sano H, Asai Y, Miyazaki M, Iwakura M, Maeda Y. Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan. Current Medical Research and Opinion 2020;36:465-71. [DOI: 10.1080/03007995.2019.1700361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Xue T, Wu X, Chen S, Yang Y, Yan Z, Song Z, Zhang W, Zhang J, Chen Z, Wang Z. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis. Sleep Med Rev 2021;61:101573. [PMID: 34902823 DOI: 10.1016/j.smrv.2021.101573] [Reference Citation Analysis]
113 Kishi T, Nishida M, Koebis M, Taninaga T, Muramoto K, Kubota N, Moline M, Sakuma K, Okuya M, Nomura I, Iwata N. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review. Neuropsychopharmacol Rep 2021. [PMID: 34553844 DOI: 10.1002/npr2.12205] [Reference Citation Analysis]
114 Sutton EL. Profile of suvorexant in the management of insomnia. Drug Des Devel Ther 2015;9:6035-42. [PMID: 26648692 DOI: 10.2147/DDDT.S73224] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
115 Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307-349. [PMID: 27998379 DOI: 10.5664/jcsm.6470] [Cited by in Crossref: 383] [Cited by in F6Publishing: 286] [Article Influence: 76.6] [Reference Citation Analysis]
116 Rhyne DN, Anderson SL. Suvorexant in insomnia: efficacy, safety and place in therapy. Ther Adv Drug Saf 2015;6:189-95. [PMID: 26478806 DOI: 10.1177/2042098615595359] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]